Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | PAM | P19021 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28823543 | 0.89 | ALDH1A1 (0.45) | FBP1MAOAMAOBCHRM2CHRM1 | |
| SCHEMBL2772413 | 0.87 | CYP1A2 (0.53) | NFE2L2FBP1MAOAMAOBCYP1A2 | |
| SCHEMBL2772409 | 0.87 | CYP1A2 (0.53) | NFE2L2FBP1MAOAMAOBCYP1A2 | |
| SCHEMBL79771 | 0.85 | PTGS1 (0.50) | NFE2L2FBP1MAOAMAOBCYP1A2 | |
| SCHEMBL10901883 | 0.85 | HSD17B3 (0.52) | MAOAMAOBMAPT | |
| SCHEMBL79770 | 0.85 | PTGS1 (0.50) | NFE2L2FBP1MAOAMAOBCYP1A2 | |
| SCHEMBL27792900 | 0.85 | LCK (0.59) | FBP1MAOAMAOBLCKCYP1A2 | |
| SCHEMBL9871756 | 0.85 | NFE2L2 (0.65) | NFE2L2FBP1CYP1A2NPC1 | |
| SCHEMBL10901886 | 0.85 | HSD17B3 (0.52) | MAOAMAOBMAPT | |
| SCHEMBL7294478 | 0.85 | NFE2L2 (0.65) | NFE2L2FBP1CYP1A2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013760-B2 | Polyguanidine polymers and methods of use thereof | SEALIFE PHARMA GMBH (AT) | 2021-05-25 | — | — | US | disclosed |
| US-11013760-B2 | Polyguanidine polymers and methods of use thereof | SEALIFE PHARMA GMBH (AT) | 2021-05-25 | — | — | US | disclosed |
| US-20190269719-A1 | POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF | SEALIFE PHARMA GMBH (AT) | 2019-09-05 | — | — | US | disclosed |
| US-20190269719-A1 | POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF | SEALIFE PHARMA GMBH (AT) | 2019-09-05 | — | — | US | disclosed |
| US-10335431-B2 | Method for producing polyguanidines | SEALIFE PHARMA GMBH (AT) | 2019-07-02 | — | — | US | disclosed |
| EP-3174848-B1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2018-08-01 | — | — | EP | disclosed |
| EP-3174848-B1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2018-08-01 | — | — | EP | disclosed |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2017-08-10 | — | — | US | disclosed |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2017-08-10 | — | — | US | disclosed |
| WO-2016015081-A9 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2016-03-31 | — | — | WO | disclosed |
| WO-2016015081-A1 | METHOD FOR PRODUCING POLYGUANIDINES | SEALIFE PHARMA GMBH (AT) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10335431-B2 | Method for producing polyguanidines | GDA, PARG, ADAR | NFE2L2 3495/4885FBP1 1577/4885CYP19A1 3660/4885 |
| US-20190269719-A1 | POLYGUANIDINE POLYMERS AND METHODS OF USE THEREOF | PUF60, PARG, ALG1 | NFE2L2 4758/4885FBP1 666/4885CYP19A1 4505/4885 |
| US-11013760-B2 | Polyguanidine polymers and methods of use thereof | PUF60, PARG, ALG1 | NFE2L2 4758/4885FBP1 666/4885CYP19A1 4505/4885 |
| US-20170224723-A1 | METHOD FOR PRODUCING POLYGUANIDINES | GDA, PARG, ADAR | NFE2L2 3495/4885FBP1 1577/4885CYP19A1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.